Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date of Report: September 16, 2026
Principal Executive Office: Marseille, France
Context: This filing incorporates by reference a press release (Exhibit 99.1) dated September 16, 2026. The document serves to update U.S. investors and incorporates the referenced material into the company's registration statements on Form F-3 and Form S-8.
Key Financial Metrics
The provided filing text is a cover sheet and incorporation by reference document. It does not contain specific financial data. Consequently, the following metrics are not available in this text:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not disclose specific material changes, financial comparisons, or operational updates versus prior periods. The substantive details regarding changes are contained within the incorporated Exhibit 99.1 (Press Release), the text of which is not included in the input.
Guidance, Outlook, and Risks
Management Commentary: The filing references a quotation from Jonathan Dickinson, Chief Executive Officer, within the incorporated press release, but the content of this commentary is explicitly excluded from the incorporation by reference in this specific Form 6-K text.
Guidance and Risks: No specific guidance, outlook, risks, contingencies, or unusual items are detailed in the provided text.
Investor Verification Checklist
- Review the full text of Exhibit 99.1 (Press Release dated September 16, 2026) to obtain the specific news, financial updates, or operational milestones announced by the company.
- Verify the content of the CEO quotation referenced in the filing, as it was excluded from the incorporation by reference in this document.
- Check the company's Form 20-F or most recent quarterly reports for the latest audited financial statements, as this Form 6-K contains no numerical data.
- Confirm the status of the registration statements (Form F-3 File No. 333-276164 and Form S-8 File No. 333-282031) to understand how this press release impacts potential capital raising activities.